Recipient organisationInfectious Diseases Institute Makerere University
Funding£2.7M
PeriodApr 2023 — Apr 2026
In plain English
AI plain-English summary
In Uganda, doctors are prescribing antibiotics to people living with HIV without knowing whether those drugs are working properly or causing harm. This matters because antimicrobial resistance (AMR) is rising fast, and people with HIV are especially vulnerable to infections. Standard antibiotic doses may not work the same way in patients who also have other conditions like diabetes or kidney disease. The research has three parts: tracking antibiotic prescribing patterns in HIV clinics, developing mathematical models to predict how antibiotics behave in patients with multiple illnesses, and testing whether pharmacy-led interventions at six regional referral hospitals can reduce unnecessary antibiotic use. If successful, this work could change how antibiotics are prescribed across low- and middle-income countries. Instead of one-size-fits-all dosing, clinicians could use real-time monitoring to tailor antibiotic therapy for individual patients. The project also builds a research network and training platform that will outlast the grant itself, strengthening Uganda’s capacity to tackle AMR long-term.
View original technical description
CAMO-NET aims to address the global impact of antimicrobial resistance (AMR) on human health via optimised antimicrobial use by establishing a sustainable global research ecosystem developed across HICs and LMICs. The CAMO-NET Uganda application is led by the Infectious Diseases Institute Makerere University (IDI) and comprises three research projects: - Investigating the patterns and trends in antibiotic prescribing among people living with HIV (PLHIV) enrolled in routine cohorts at IDI Clinics. This project will include qualitative studies and cohort analyses to improve understanding of antibiotic prescribing in an LMIC HIV clinic. - Innovative approaches to optimize antibiotic therapy for patients with multimorbidity in an outpatient HIV clinic in Uganda. This project will develop a multidisciplinary clinical platform for optimizing antibiotic use in the context of multimorbidity among PLHIV, develop, validate a population pharmacokinetic-pharmacodynamic models for selected antibiotics and evaluate innovative point of care therapeutic drug monitoring and its adoption for selected antimicrobials in PLHIV. - Understanding trends in antibiotic consumption and use among patients attending six regional referral hospitals in Uganda to inform and evaluate pharmacy staff-led interventions. Additionally, IDI will serve as capacity-building lead providing a platform for collaborative and capacity-strengthening activities for CAMO-NET consortium partners.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know